This study looks at how a new medicine called NMRA-335140 helps people with Major Depressive Disorder (MDD). MDD is a serious type of depression. The study is "double-blind", meaning neither the participants nor the researchers know who is getting the real medicine or a "placebo" (a harmless pill). The study lasts 6 weeks, but it starts with a "Screening Period" that can last up to 35 days to make sure participants fit the study rules. Participants may continue with the medicine in an "open-label extension", where everyone knows they are getting NMRA-335140, if they meet certain criteria.
To join, participants should have a doctor-confirmed diagnosis of MDD, with symptoms lasting over 4 weeks but less than a year. They should not have certain other mental health conditions or be actively suicidal. People who have not responded to at least two antidepressants in the past may not join.
NCT06058039
Neumora Therapeutics, Inc.
8 July 2024
Congrats! You have your own personal workspace now.